Valneva (NASDAQ:VALN) Shares Gap Up – Should You Buy?

Valneva SE (NASDAQ:VALN) shares gapped up prior to trading on Wednesday . The stock had previously closed at $5.61, but opened at $6.21. Valneva shares last traded at $6.27, with a volume of 10,865 shares traded.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Valneva in a report on Friday, January 31st.

Valneva Price Performance

The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The stock’s 50-day simple moving average is $4.52 and its two-hundred day simple moving average is $5.66.

Hedge Funds Weigh In On Valneva

An institutional investor recently bought a new position in Valneva stock. ABC Arbitrage SA purchased a new stake in Valneva SE (NASDAQ:VALN) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 19,244 shares of the company’s stock, valued at approximately $84,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.